SWK — Investor Presentation (May 2018)
44 slides from SWK's investor presentation, May 17, 2018
Slide 1: Collaborative Approach to Life Science Financing
Collaborative Approach to Life Science Financing
Slide 2: Forward-looking and Cautionary Statements
Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that webelieve or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities l
Slide 3: Corporate Overview
LL ASWK HoLvives CORPORATE OVERVIEW
Slide 4: SWK Holdings Overview
SWK Holdings Overview SWK provides custom financing solutions for commercial-stage healthcare companies and royalty owners Deploys balance sheet capital into secured financing portfolio - Market capitalization at 5/15/18 was $136mm, 64% of 3/31/18 stockholders equity of $212mm SWK targets $5mm to $2
Slide 5: Why Life Science Finance?
Why Life Science Finance? Achieve high current yield from investment in non-correlated assets - Invest in royalty, revenue, equity & debt interests from healthcare companies, research institutions and inventors - Structured debt: high coupon drives current yield and warrants provide equity upside; b
Slide 6: Experienced Team
Experienced Team SWK’s investment professionals have extensive experience financing life science companies CEO Winston Black has been active in life science structured finance asset class since 2007 when he helped manage a multi-billion dollar healthcare portfolio for a large investment firm and hel
Slide 7: Corporate Milestones
Corporate Milestones 7 Pre- 2012 2012 2013 2014 2015 2016 2017 • Predecessor Kana Software assets sold to Kay Technologies; $450mm+ NOLs remained at sale • SWK exists as public shell • Winston Black and Brett Pope hired to launch life science technology finance strategy • Holmdel formed and acquired
Slide 8: Value Creation Strategy
Value Creation Strategy Deploy balance sheet capital into secured financing portfolio - $5mm to $20mm loan and royalty market sports attractive, low-to-mid teens yields - SWK has established reputation as a go-to capital provider for this underserved market - Majority of financings structured with w
Slide 9: Portfolio Overview: 3/31/18
*Private warrants carried at zero cost **One financed entity was repaid on May 1, 2018 Portfolio Overview: 3/31/18 9 •GAAP Value: $169.1mm •Finance Receivables: $165.8mm •Marketable Securities: $1.7mm •Public Warrants: $1.5mm * Portfolio Value •Actively Financed Entities: 20 ** •Avg. GAAP Balance pe
Slide 10: SWK Key Statistics
SWK Key Statistics 10 * Defined as finance receivables, marketable investments and investment in unconsolidated entity less non-controlling interests ** During 2017 SWK incurred a $15.7mm provision for income taxes to reduce the carrying value of the deferred tax asset to account for a reduction in
Slide 11: SWK Targets Low-to-Mid Teens Effective Yields
SWK Targets Low-to-Mid Teens Effective Yields 11 *Includes non-accruals; Excludes warrants **Includes non-accruals; Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies, if all payments are received pursuant to the terms of t
Slide 12: SWK Employs a Lean Cost Structure
SWK Employs a Lean Cost Structure 12 SWK is internally managed and does not engage outside advisors to fulfill the investment function Management receives a fixed salary and participates in a bonus pool based on the Company’s annual pre-tax profit CORPORATE OVERVIEW
Slide 13: Investment Process
LL ASWK HoLvives INVESTMENT PROCESS
Slide 14: Underwriting Process Overview
Underwriting Process Overview Sourcing Initial Analysis and Screening Detailed Diligence Preliminary Term Submission Investment Committee Approval and Term Sheet Monitoring Legal Documentation 14 • Financing prospects are sourced via proprietary network and brokers • Initial diligence focuses on med
Slide 15: Sourcing
Sourcing SWK has a well-developed and diversified sourcing network - SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers SWK typically faces limited competition due to proprietary sourcing network and focus on sub-$20mm financings The deals compl
Slide 16: 2017 Proposals and Win Rate
2017 Proposals and Win Rate In 2017 SWK evaluated approximately 69 financings * - Similar activity count in 2016 with 75 opportunities evaluated SWK proposed preliminary terms on 30 financings - The 30 financings represented $267mm of SWK capital and $350mm including partners SWK closed three transa
Slide 17: Diligence Process
Diligence Process SWK’s diligence process is anchored by the “four Cs” of credit analysis: Collateral, Character, Capacity, and Capital Collateral value is ascertained through analysis of medical and commercial need, market size, IP, and potential strategic buyers and historical transaction valuatio
Slide 18: Current Portfolio
LL ASWK HoLvives CURRENT PORTFOLIO
Slide 19: 3/31/18 Portfolio Overview
3/31/18 Portfolio Overview Financing (Month Closed) Type Primary Product Product Marketer Funded Amount / Principal GAAP Value Effective Rate Besivance (4/2013) Royalty Ophthalmic antibiotic Valeant $6.0mm $2.6mm N/A Cambia (4/2013& 6/2015) Royalty NSAIDmigraine treatment Depomed $8.5mm $6.6mm N/A F
Slide 20: 3/31/18 Portfolio Overview (Continued)
3/31/18 Portfolio Overview (Continued) Financing (Month Closed) Type Primary Product Product Marketer Funded Amount / Principal GAAP Value CouponRate Celonova (7/2017) First Lien Medical device Self and Boston Scientific $7.6mm $7.5mm LIBOR (2.0% floor) +11.0% DxTerity Diagnostics (7/2015) First Lie
Slide 21: 3/31/18 Portfolio Overview (Continued)
3/31/18 Portfolio Overview (Continued) 21 Financing (Month Closed) Type Primary Product Product Marketer Funded Amount / Principal GAAP Value CouponRate SolsysMedical (f/k/a Soluble Systems) (6/2015) First Lien Wound care Self $15.1mm $15.1mm LIBOR (1.5% floor;3.0% cap) +10.25% TenexHealth (7/2016)
Slide 22: Realizations and Case Studies
REALIZATIONS AND CASE STUDIES
Slide 23: Portfolio Realizations
Portfolio Realizations SWK has exited twelve financings for a total 1.2x CoCreturn and 20% weighted average IRR - Ten resulted in positive realizations with a cumulative 1.4x CoCand weighted average 30% IRR - SynCardiaposition was sold to distressed private equity firm with SWK recouping 58% of prin
Slide 24: Portfolio Realizations to Strategic Buyers
Portfolio Realizations to Strategic Buyers Nine realizations to strategic buyers demonstrated an average 32% LTV of SWK’s original loan value Six of the nine businesses were not profitable at time of sale, validating SWK’s revenue and IP-based underwriting methodology 24 REALIZATIONS AND CASE STUDIE
Slide 25: Historical Financing: Holmdel Pharmaceuticals, LP
Historical Financing: Holmdel Pharmaceuticals, LP In December 2012 SWK acquired a limited partnership interest in Holmdel Pharmaceuticals Holmdel subsequently acquired U.S. marketing rights to InnoPranXL, a non-selective beta blocker with dosing technology to coincide with the body’s natural circadi
Slide 26: Current Financing: Narcan Royalty
Current Financing: NarcanRoyalty Narcanis the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcanis appropriately priced with revenue growth from expanded distribution, not price hikes Opiantis a publicly traded drug development company that receives a royalty
Slide 27: Historical Financing: Galil Medical
Historical Financing: GalilMedical Galilis a medical device company that delivers innovative cryotherapy solutions for tumor ablation In 2014 the privately-held company was on the cusp of accelerating revenue growth, but was not yet cash-flow positive and could not tap traditional financing channels
Slide 28: Historical Financing: SynCardia
Historical Financing: SynCardia SynCardia manufactures and markets the only FDA-approved artificial heart SWK’s original thesis: - Device approved in US and EU; positive efficacy in over 1,300 implants - Device reimbursed at $125,000 in US and $70,000 outside the US - Large and untapped market with
Slide 29: Miscellaneous
LL ASWK HoLvives MISCELLANEOUS
Slide 30: SWK Value Proposition to Partners
SWK Value Proposition to Partners SWK’s asset base and nimble structure position it to serve the sub-$20mm financing market - Smaller companies often don’t have financial profile to qualify for traditional financing sources - Companies in this niche often have few options outside of a dilutive equit
Slide 31: Financing Structures
Financing Structures Structured debt - Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities - Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage - Provide working capital to support product commercializa
Slide 32: Illustration: Royalty Stream Creation
Illustration: Royalty Stream Creation Small Biotech enters into marketing collaboration with Big Pharma 1. Small Biotech licenses marketing rights of Drug A to Big Pharma in exchange for upfront payment and a 10% royalty stream 2. Big Pharma markets the drug and begins to pay a 10% royalty stream on
Slide 33: Biographies and Contact Information
BIOGRAPHIES AND CONTACT INFORMATION
Slide 34: Biographies: Winston Black, CEO
Biographies Winston Black, CEO Mr. Black was appointed CEO in January 2016. He joined SWK as Managing Director in May 2012 from PBS Capital Management, LLC,aninvestment management business investing in pharmaceutical royalties and healthcare equities that Mr. Black co-founded in 2009. Prior to PBS C
Slide 35: Biographies: Jody Staggs, VP
Biographies Jody Staggs, VP Mr. Staggs joined SWK Holdings as a Senior Analyst in August 2015. Prior to joining SWK, he was Vice President of Investments atAnnandale Capital. Prior to joining Annandale, he was the first employee at Alistair Capital, a Dallas-based hedge fund. He previously co-founde
Slide 36: Biographies: Yvette Heinrichson, Controller
Biographies Yvette Heinrichson, Controller Ms. Heinrichson joined SWK Holdings as Controller in January 2016. Prior to joining SWK, she provided technical GAAP accounting,SEC financial reporting, SOX implementation and process improvement for companies in a number of industries including healthcare/
Slide 37: Biographies – Board of Directors
Biographies –Board of Directors Michael D. Weinberg, Chairman of the Board Mr. Weinberg is Chief Operating Officer of Carlson Capital, L.P. Mr. Weinberg has served in various capacities with Carlson since November 1999. Since April 2007, Mr. Weinberg has served as the managing member of BirdDogCapit
Slide 38: Biographies – Board of Directors
Biographies –Board of Directors Edward Stead Mr. Stead has served as a senior executive for various companies over an extensive business career. Mr. Stead began his career as a lawyer at IBM from 1973 to 1985. He then served at Apple Computer, Inc. from 1987 until 1996, where he held titles up to an
Slide 39: Contact Information
Contact Information Winston Black: - Phone: 972.687.7251 - Email: [email protected] Jody Staggs: - Phone: 972.687.7252 - Email: [email protected] Office address: - 14755 Preston Road, Ste105 Dallas, TX 75254 Website: www.swkhold.com 39 BIOGRAPHIES AND CONTACT INFO
Slide 40: Financial Overview
LL ASWK HoLvives FINANCIAL OVERVIEW
Slide 41: Balance Sheets
Balance Sheets 41 FINANCIAL OVERVIEW $ in 000s Mar-18 Dec-17 Dec-16 Dec-15 ASSETS Cash and cash equivalents 21,451$ 30,557$ 32,182$ 47,287$ Accounts receivable 1,579 1,637 1,054 1,127 Finance receivables 165,843 151,995 126,366 99,346 Marketable investments 1,713 1,856 2,621 5,286 Investment in unco
Slide 42: Income Statements
Income Statements 42 FINANCIAL OVERVIEW $ in 000s LTM Dec-17 Dec-16 Dec-15 Revenues Finance receivable interest income, including fees 29,038$ 26,877$ 15,747$ 17,265$ Marketable investments interest income - - 92 266 Income related to investments in unconsolidated entities 326 10,530 6,219 5,884 Oth
Slide 43: Cash Flow Statements
Cash Flow Statements 43 FINANCIAL OVERVIEW $ in 000s,* LTM Dec-17 Dec-16 Dec-15 Cash flows from operating activities: Consolidated net income $1,627 $8,251 $32,041 ($4,363) Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated ent
Slide 44: Reconciliation of Non-GAAP Adjusted Net Income Attributable to SWK Stockholders
Reconciliation of Non-GAAP Adjusted Net Income Attributable to SWK Stockholders The table below eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and SWK’s warrant liability, as well as, warrant-related debt issuance costs and stock compensation expense relate